
Structure Therapeutics fell 54.3% from $35.30 to $16.13, behind the S&P 500's +3.2%. Its worst day was Sep 8 (−14.7%), and its low came Nov 20 at $16.13.
Nov 24, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Structure Therapeutics shares rose 102.5%, while the S&P 500 fell 0.3%.
+102.5%, the year's best day, on 20M shares, the year's heaviest volume · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
Structure Therapeutics closed at its highest level of the year, 165.7% above where the year started.
+3.0% · S&P 500 +1.2%
EPS of $-0.36 beat the $-0.36 estimate on $0.00 revenue (est. $200.0M).
−2.7% · S&P 500 −0.5%
EPS of $-0.35 missed the $-0.33 estimate on $0.00 revenue (est. $11.1M).
−0.1% · S&P 500 +0.8%
EPS of $-0.49 missed the $-0.38 estimate on $0.00 revenue.
+1.0% · S&P 500 +0.6%
EPS of $-0.66 missed the $-0.29 estimate on $0.00 revenue (est. $50.0M).
+1.5% · S&P 500 −0.4%
Where it ended: a close of $16.13 on Nov 20, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.33).
Nothing in the past 12 months.
All GPCR dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for GPCR and SPY from Benzinga historical bars. Not investment advice.